Filgrastim Dosing Recommendations
For chemotherapy-induced neutropenia prophylaxis in adults, use filgrastim 5 mcg/kg/day subcutaneously starting 1-3 days after chemotherapy and continue until ANC reaches 2-3 × 10⁹/L; for peripheral blood stem cell mobilization, use 10 mcg/kg/day for 4 days before leukapheresis. 1
Adult Dosing
Chemotherapy-Induced Neutropenia Prophylaxis
- Standard dose: 5 mcg/kg/day subcutaneously 1
- Timing: Start 1-3 days after myelotoxic chemotherapy completion 1
- Duration: Continue daily until ANC recovers to 2-3 × 10⁹/L 1
- Route: Subcutaneous administration is preferred 1
In high-dose therapy with autologous stem cell rescue, filgrastim can be started 1-5 days after high-dose therapy 1. The ASCO guidelines emphasize continuing prophylaxis through all chemotherapy cycles—women receiving pegfilgrastim only during the first two cycles had 36% febrile neutropenia rates versus 10% when given through all six cycles 1.
Peripheral Blood Stem Cell Mobilization
- Mobilization dose: 10 mcg/kg/day subcutaneously 1
- Timing: Start 4 days before first leukapheresis 1
- Duration: Continue through last leukapheresis procedure 1
The higher 10 mcg/kg/day dose is preferable for PBPC mobilization compared to the 5 mcg/kg/day used for neutropenia prophylaxis 1. Research supports that 10 mcg/kg/day for 5 days with leukapheresis on day 6 is highly effective, with all donors achieving potentially sufficient GM-CFC yields (≥50 × 10⁴/kg) 2.
Pediatric Dosing
Chemotherapy-Induced Neutropenia Prophylaxis
For pediatric patients, use the same weight-based dosing as adults: filgrastim 5 mcg/kg/day subcutaneously starting 1-3 days after chemotherapy. 3
- Dose: 5 mcg/kg/day subcutaneously 3
- Timing: At least 24 hours after chemotherapy completion 3
- Duration: Continue until neutrophil recovery 3
A 2025 randomized trial in 61 pediatric patients demonstrated that this dosing significantly reduced febrile neutropenia incidence (18% with filgrastim versus 8% with pegfilgrastim) 4. The evidence shows filgrastim decreases duration of fever, hospital stay, and antibiotic use in high-risk pediatric patients 3.
Severe Chronic Neutropenia (Pediatric-Specific)
The dosing varies by neutropenia type 1, 5:
- Idiopathic neutropenia: Start at 3.6 mcg/kg/day
- Cyclic neutropenia: Start at 6 mcg/kg/day
- Congenital neutropenia: Start at 6 mcg/kg/day divided twice daily
Doses can be increased incrementally to 12 mcg/kg/day divided twice daily if no response 1, 5.
Critical Timing Considerations
Do not administer filgrastim within 24 hours before or after cytotoxic chemotherapy to avoid potential stimulation of rapidly dividing myeloid cells during chemotherapy exposure 5. The optimal window is 1-3 days post-chemotherapy 1.
For bone marrow transplantation, filgrastim should be initiated on the day of bone marrow infusion, not within 24 hours after last chemotherapy and 12 hours after most recent radiotherapy 1.
Important Caveats
Pediatric Leukemia Warning
Routine use of filgrastim cannot be recommended for children with de novo acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). 1 While filgrastim shortened neutropenia duration in pediatric AML trials, it did not decrease febrile neutropenia, documented infections, or infection-related mortality, and there remains theoretical concern about stimulating leukemic blast growth 1.
Weight-Based Dosing Pitfall
The commercially available 300 mcg and 480 mcg vials create practical dosing challenges. For patients weighing >60 kg where ideal dose exceeds 300 mcg but is less than 480 mcg, clinicians often use 300 mcg to avoid waste 6. While a two-day course of 300 mcg showed adequate responses in patients <85 kg, infection rates increased significantly in patients >85 kg (33% versus 5% in medium weight group) 6.
Alternative: Pegfilgrastim
For patients unable to return for daily injections, pegfilgrastim 6 mg as a single dose 1-3 days after chemotherapy is an effective alternative 1. However, the 6 mg formulation should not be used in infants, children, or small adolescents weighing <45 kg 1. In pediatrics, pegfilgrastim 100 mcg/kg single dose is appropriate for patients ≥45 kg 3.